Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were included.
Specific interventions included in the review
Various adjuvant treatments including chemotherapy, radiotherapy alone or in combination with chemotherapy, and chemoimmunotherapy. The drugs studied were: thiotepa, 5-fluorodeoxyuridine, mitomycin C, 5-fluorouracil, adriamycin, vincristine, cyclophosphamide, methyl CCNU, vinblastine, 1,3-bis(2 chlorethyl)-1-nitrosourea, tegafur, cytosine arabinoside, ftorafur, levamisole, picibanil, SPG, futraful, bestatin, poly AU, FT 207, BCG, N-CWS and PSK.
Participants included in the review
Patients with adenocarcinoma of the stomach who had received adjuvant treatment following surgery (curative, non-curative, palliative or unresectable).
Outcomes assessed in the review
Survival, response rates, toxicity, rates of recurrence and liver metastases.
How were decisions on the relevance of primary studies made?
The author does not state how the papers were selected for the review, or how many of the reviewers performed the selection.